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Twenty B candidate epitopes of glycoproteins B (gB2), C (gC2), E (gE2), G (gG2), and I (gI2) of herpes simplex virus type 2
(HSV-2) were predicted using DNAstar, Biosun, and Antheprot methods combined with the polynomial method. Subsequently,
the biological functions of the peptides were tested via experiments in vitro. Among the 20 epitope peptides, 17 could react with
the antisera to the corresponding parent proteins in the EIA tests. In particular, ﬁve peptides, namely, gB2466–473 (EQDRKPRN),
gC2216–223 (GRTDRPSA), gE2483–491 (DPPERPDSP), gG2572–579 (EPPDDDDS), and gI2286–295 (CRRRYRRPRG) had strong reaction
with the antisera. All conjugates of the ﬁve peptides with the carrier protein BSA could stimulate mice into producing antibodies.
The antisera to these peptides reacted strongly with the corresponding parent glycoproteins during the Western Blot tests, and the
peptides reacted strongly with the antibodies against the parent glycoproteins during the EIA tests. The antisera against the ﬁve
peptides could neutralize HSV-2 infection in vitro, which has not been reported until now. These results suggest that the immuno-
dominant epitopes screened using software algorithms may be used for virus diagnosis and vaccine design against HSV-2.
1.Introduction
Herpes simplex virus type 2 (HSV-2) mainly causes genital
infections [1]. HSV-2 glycoproteins are structural compone-
nts of the virion envelope and have been implicated in virus-
induced alterations of mammalian cells [2, 3]. Moreover,
HSV-2 glycoproteins are expressed in infected cell plasma
membranesandactasmajorantigenicstimuliforthecellular
and humoral responses of a host [2, 3]. Some virion glyco-
proteins, such as glycoproteins B (gB2), C (gC2), and E
(gE2), have been described [4]. Glycoproteins G (gG2) and
I (gI2) and gB2, gC2, and gE2 apparently play major roles in
immuneresponsestoHSV-2.Evidencesupportthefollowing
s u g g e s t i o n s :( i )t h ep u r i ﬁ e dg B 2 ,g C 2 ,g E 2 ,g G 2 ,a n dg I 2o f
HSVtype1(oral,HSV-1)orHSV-2(genital)stimulatedhigh
titers of type-common virus-neutralizing antibodies [5, 6];
(ii) passive immunizations with the monoclonal antibodies
against gB2, gC2, gE2, gG2, and gI2 protected mice from the
infection using a lethal dose of HSV [7–9]; (iii) gB2, gC2,
gE2, gG2, and gI2 mediated antibody-dependent, comple-
ment-mediated cytotoxicity and antibody-dependent, cell-
mediated cytotoxicity [7, 10, 11]; (iv) the puriﬁed gB2, gC2,
gE2, gG2, and gI2 were able to protect mice against lethal
infection with either HSV-1 or HSV-2.
We have recently predicted and identiﬁed the epitopes of
gD2 involved in its biological and immunological activities2 Clinical and Developmental Immunology
using a panel of gD2-speciﬁc antibodies that recognized four
separate antigenic epitopes on the molecule. Some epitopes
are type-speciﬁc and have strong virus-neutralizing activity
in vitro. In the current study, 20 immunodominant epitopes
fromﬁveproteinsofHSV-2,namely,gB2,gC2,gE2,gG2,and
gI2,werepredictedandvalidatedviaexperiments. Fiveofthe
20epitopeshadstrongantigenicityandimmunogenicity,and
thus they could protect the mice from HSV-2 infection.
2.MaterialsandMethods
2.1. General Materials and Animals. Medium199 (Applichem)
contained 5% newborn calf serum, antibiotics, and 20mM
N-2-hydroxyethylpiperazine-N -2-ethanesulfonic acid (HE-
PES). Bio-Rad miniprotean cell (Hercules, CA, USA), nitro-
cellulose membrane (Amersham, Arlington Heights, IL,
USA), peroxidase-labeled goat anti-mice immunoglobulin G
(Boster,China), andECL detectionsystem(Amersham,Pha-
rmacia Biotech, Uppsala, SE, Sweden) were used in the cur-
rent experiment. Antibodies to gB2, gC2, gE2, gG2, and gI2
were bought from ABcam Company. The mice (KM, China,
4–6 weeks old, female) were purchased from the Animal
Centre in Anhui University of Traditional Chinese Medicine.
2.2. Epitope Prediction and Synthesis. T h eB - c e l la n t i -
genic epitope analysis on six glycoproteins, namely, gB2
(AAA60540.1 gI2: 6234000), gC2 (AAA66442.1 GI: 330266),
gE2 (ABU45439.1 gI2: 156072176), gG2 (ABI32310.1 GI:
113200389), and gI2 (ACA28832.1 GI: 168805625) from
HSV-2, was based on three related software algorithms,
namely, Biosun, DNAstar, and Antheprot. B-cell epitopes
were predicted by referring to the parameters, such as β-turn
occurrence, hydrophilicity, surface probability, and ﬂexibili-
ty, which have been shown to be indicative of potentially
antigenic regions. The peptides comprising Asn-X-Thr/Ser
sequences (glycosylation sites), proposed membrane-spann-
ing regions, and C-terminal membrane-anchor sequences
were excluded. The peptides showing common results from
the software algorithms above were selected as candidate epi-
topes. The antigenic, surface-located regions (B-cell epitope)
of the primary structure of the glycoproteins from HSV-2
should be predicted to generate the antibodies that might be
reactive with the glycoproteins and possibly neutralize viral
infectivity [12–14]. Some nonepitope peptides conﬁrmed
using EIA tests were selected as the controls. The Jinsite
Company (China) chemically synthesized the screened epi-
tope peptides.
2.3. Antigenicity Analysis Using EIA Tests. The antigenicity of
the predicted epitopes was determined using EIA with the
antibodies to the corresponding parent glycoproteins (gB2,
gC2, gE2, gG2, and gI2). 96-well plates were coated with
free peptides in 100μL( 2 . 5μg / m L )o f5 0m Ms o d i u mb i c a r -
bonate buﬀer/0.6M NaCl (pH value of 9.6) for each well at
4◦Covernight.Thenextday,130μLofblockingsolution(1 ×
PBS, 1% bovine serum albumin) was added into each well
after washing the plates ﬁve times with PBST at 4◦Co v e r -
night. The antibodies of the ﬁve proteins gB2, gC2, gE2,
gG2, and gI2 were diluted using 1:100 and then a twofold
serial dilution. Consequently, 100μL was added into each
well and then incubated at 37◦Cf o r1 h .T h ep l a t e sw e r e
washed ﬁve times with PBST. Subsequently, 100μLo f
1:10000dilutedperoxidase-labeledgoatanti-miceimmuno-
globulin G (Boster) was added into each well and then incu-
bated at 37◦C for 1h. All antibodies or antisera were dilut-
ed with phosphate-buﬀered saline (PBS) supplemented with
0.2M NaCl and 0.3% Tween 80. The plates were washed ﬁve
times with PBST, and the color was developed by adding
100μL of TMB substrate, which was a solution of peroxide
(0.006%, vol/vol) and o-phenylenediamine (0.02%, wt/vol)
in 2% methanol-50mM sodium phosphate buﬀer (pH value
of 5.6), incubated at 37◦C for 10min in the dark. The reac-
tion was stopped by adding 50μLo f2MH 2SO4. The A450
value was then measured using a Titertek Multiscan spectro-
photometer (Titertek, Helsinki, Finland).
2.4. Conjugation of Peptides to Carrier BSA. Conjugation of
peptides to carrier BSA was performed according to the
reported methods [15]. After the conjugation reaction, the
samples were dialyzed against PBS (pH value of 7.4). The
molar peptide/BSA ratio in the various conjugates was deter-
mined via the amino acid analyses on the peptide-carrier
conjugate and the untreated BSA. The molar peptide/BSA
ratios were 5 to 10. Peptide carrier conjugates were stored at
−20◦C.
2.5. Mice Immunization and Antisera Preparation. Twenty
miceweredividedintotwogroupswith10miceeach.Appro-
ximately, 4μg of peptide-BSA was then emulsiﬁed in com-
plete Freund’s adjuvant and was injected subcutaneously for
the ﬁrst injection of each mouse. Approximately 2μgo f
the puriﬁed peptide-BSA emulsiﬁed in incomplete Freund’s
adjuvant was injected subcutaneously after 14 days for the
second injection. The third injection was similar to the sec-
ond injection. The PBS, as a control, was injected using the
same above-mentioned procedure. Blood samples were col-
lected 14 days after the third immunization and were then
stored at −20◦C.
2.6. Peptide Immunogenicity Detection Using EIA. Peptide-
BSA-speciﬁc IgG antibodies in the antisera were determined
using an endpoint EIA with the peptide-BSA as antigens, as
described previously [16] .T h et i t e r sw e r ee x p r e s s e da st h e
reciprocalsofthehighestdilutionoftheserawithratiovalues
of 2.1. Moreover, proteins gB2, gC2, gE2, gG2, and gI2 were
used as antigens for detecting the antisera using EIA.
2.7. Peptide Speciﬁcity Analysis Using Western Blot. Approx-
imately 10μL of peptides-BSA conjugation was separated
using 10% SDS-PAGE with a Bio-Rad miniprotean cell (Her-
cules, CA, USA) and then transferred to a strip of nitrocel-
lulose membrane (Amersham, Arlington Heights, IL, USA).
The nitrocellulose strip was blocked using a blocking buﬀer
(5% skim milk in 20mM Tris-HCl, pH 7.5, with 500mM
NaCl, 0.05% Tween 20) and was then shaken for 2h at 37◦C
or overnight at 4◦C. Subsequently, the strip was incubatedClinical and Developmental Immunology 3
with the antiserum diluted 1:50–1:10000 using a blocking
buﬀer and was then shaken for 2h at 37◦C or overnight at
4◦C.Themembranewasthenwashedfor3minto5minwith
PBST ﬁve times. The HRP-labeled goat anti-mouse anti-
bodies (Boster, China) at 1:10000 dilution was added into
the strip and was incubated at 37◦C for 1h. The membrane
was washed 3min to 5min with PBST ﬁve times, and then
the luminescence substrate was added, exposing an X-ray
ﬁlm using an ECL detection system (Amersham, Pharmacia
Biotech, Uppsala, SE, Sweden) in a dark room.
2.8. Virus Neutralization Test. The antisera for the neutral-
ization of HSV-2 (strain Sav) in vitro were assayed using the
50% plaque reduction assay [17]. The antisera were inacti-
vated at 56◦C for 30min to inactivate the complements. The
antisera were diluted using 1:4, followed by twofold serial
dilutions, and were then incubated with an equal volume of
HSV-2 (150μL, 600 PFU). HSV-2 viruses and the sera were
diluted with medium 199 (Applichem), which contained 5%
newborn calf serum, antibiotics, and 20mM N-2-hydroxy-
ethylpiperazine-N -2-ethanesulfonic acid (HEPES). Approx-
imately 100μL of the incubation mixture was plated into
the monolayers of the Vero cells grown in 6-well trays for
each well after 2h incubation at 37◦C. An overlay medium
containing 0.5% methylcellulose was then added into the
mixtureafter1hadsorption at37◦C.Thecellswereﬁxedand
then stained with Giemsa solution after 2-3 days of storage
at 37◦C. Plaques were counted, and the neutralization titer
was calculated as the reciprocal of the serum dilution times
yielding a 50% plaque reduction.
2.9. Animal Protection Experiments. S i x t ym i c ew e r er a n -
domlydividedintosixgroupswith10miceeach.Fivegroups
were immunized with the ﬁve epitopes, respectively, and the
last group was immunized with PBS as the control. Each
mouse was subcutaneously immunized thrice using 8μgo f
the epitope peptide, with a two-week interval between im-
munizations. Approximately, 4μg of epitope peptide emul-
siﬁed in complete Freund’s adjuvant was used for the ﬁrst
immunization, 4μg of epitope peptide emulsiﬁed in incom-
plete Freund’s adjuvant was used for the second immuniza-
tion, and 4μg of epitope peptide alone was used for the
ﬁnal immunization. The control group was immunized with
PBS using the same procedure. The mice were anesthetized
and were then challenged with the HSV-2 Sav strain three
weeks after the ﬁnal immunization. The immunized and
sham-immunized mice were subcutaneously injected with
2mg of progesterone (Jinsite, China) in 50μLo fH 2Op e r
mouse to synchronize the estrus cycle at the progesterone-
dominated stage. On the 5th day after the administration
of progesterone, all the mice were challenged with HSV-2
Sav strain through their vagina and external genital skin.
The vaginal closure membrane was ruptured with a saline-
moistened cotton swab an hour prior to the virus challenge.
Theswabwasinserted into thevagina of eachmouse, twisted
b a c ka n df o r t hﬁ v et i m e s ,a n dt h e nr e m o v e da n dw i p e do v e r
the external genitalia. The infected mice were examined daily
forvaginal inﬂammation, neurological illness, and death and
were then scored in grades 1–5 depending on the severity
of the disease, as described in a reported paper [17]. The
survival ratio of the mice was calculated daily.
2.10. Statistical Analysis. Data were the mean values of at
leastthreediﬀerentexperimentsandexpressedasmean ±SD.
Student’s t-test was used to compare diﬀerent data sets. The
diﬀerences between groups were compared with one another
using one-way ANOVA. P<0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Prediction and Identiﬁcation of B-Cell Epitopes. Twenty
B-cell immunodominant epitopes in glycoproteins gB2, gC2,
gE2, gG2, and gI2 of HSV-2 were predicted using the DNAs-
tar algorithm. The predicted β-turn, ﬂexibility, coil regions,
glycosylation sites, and antigen value of the epitopes are
listed in Table 1. The antigenicity of the predicted immun-
odominantepitopeswasdetectedusingEIAoftheantibodies
to their corresponding parent glycoproteins. The epitope
peptides were coated as antigens in 96-well plates, with
100μL(2.5μg/mL)ineachwell.Theantibodiestothecorres-
ponding parent glycoproteins gB2, gC2, gE2, gG2, and gI2
(ABcam) reacted with the epitopes, respectively. The A450
values were measured, and the results (Table 1) show that
17 out of the 20 epitopes had various levels of antigeni-
city. Three epitopes, namely, gB2468–475,g B 2 300–306,a n d
gC2326–335, were predicted to have strong antigenicities using
the software algorithms, but their antigenicities were shown
to be weak in the EIA tests (Table 1). Overall, combin-
ing the prediction results using the three software algo-
rithms (Table 1) with the EIA results (Tables 1 and
2), at least ﬁve epitopes (listed in Table 1 in bold),
namely, gB2466–473 (EQDRKPRN), gC2216–223 (GRTDRPSA),
gE2483–491 (DPPERPDSP), gG2572–579 (EPPDDDDS), and
gI2286–295 (CRRRYRRPRG), were conﬁrmed as strong B cell
antigenic epitopes. All conjugates of the ﬁve peptides with
the carrier protein BSA could stimulate mice into producing
antibodies.Moreover,theantiseratotheﬁvepeptidesreacted
strongly with the corresponding parent glycoproteins during
the EIA tests, and the peptides reacted strongly with the
antibodies against the corresponding parent glycoproteins
during the EIA tests (Table 2).
3.2. Speciﬁcity of Antipeptide Antibodies. The speciﬁcity of
the antisera to the ﬁve epitopes was examined further using
WesternBlotanalysis.Theepitope-BSAconjugateswereused
as antigens for detecting the antibodies to the corresponding
parent proteins and as antisera to the ﬁve epitopes detected
with the corresponding parent proteins gB2, gC2, gE2, gG2,
and gI2. The results (Table 3, Figures 1 and 2) show that
the epitope-BSA conjugates reacted speciﬁcally with the
antibodies to the corresponding parent proteins without any
cross-action and that the antisera to the ﬁve epitopes could
react with the corresponding parent proteins.4 Clinical and Developmental Immunology
Table 1: Predicted antigenicity (antigen value) of the 20 epitopes and the EIA detection results.
Number Predicted
epitope
Surface
probability Flexibility β-turn Coil
Glycosylation
site Asn-X-
Thr/Ser
Predicted
antigen
value
EIA A450 value
(1) gB258–75 5.219 44–82 69, 71 69, 70 1.588 0.361 ±0.011
(2) gB2466–473 5.685 465–485 473 470 2.31 0.987 ±0.031
(3) gB2468–475 4.185 465–475 473 470 + 1.593 0.276 ±0.011
(4) gB2300–306 1.984 300–306 301 301–305 2.057 0.118 ±0.024
(5) gC2326–335 1.320 328–335 330–332 333–335 + 2.044 0.278 ±0.011
(6) gC295–105 1.315 95–100 93, 98 100–104 2.01 0.687 ±0.022
(7) gC2161–171 1.948 161–170 167 164–170 + 1.736 0.689 ±0.021
(8) gC2216–223 2.242 216–223 217, 222 219–223 2.235 0.898 ±0.030
(9) gE2514–522 3.446 514–522 519 515 2.322 0.655 ±0.030
(10) gE2471–479 2.02 471–479 478 471–47 2.287 0.877 ±0.031
(11) gE2483–491 2.972 484–495 488, 492 485, 493 2.367 1.107 ±0.042
(12) gE2385–398 2.701 385–398 396 385–394 2.49 0.564 ±0.021
(13) gG2526–539 2.613 526–537 535, 539 530, 534 1.866 0.456 ±0.019
(14) gG2286–295 1.215 289–293 290 288 1.56 0.821 ±0.025
(15) gG2572–579 2.767 569–577 569, 574 570 2.807 0.811 ±0.031
(16) gG2350–364 1.844 350–364 351 353–358 2.124 0.992 ±0.033
(17) gI2202–226 2.453 202–226 203, 210, 217 205 + 1.859 0.413 ±0.011
(18) gI2236–253 2.143 236–253 242, 253 241, 244–9, 251 2.081 0.856 ±0.026
(19) gI2286–295 4.729 287–295 287, 293 2.764 1.034 ±0.039
(20) gI2319–337 3.427 319–337 323, 326, 333 321, 325, 335 2.042 0.569 ±0.021
C 0.121 ±0.011
Table 2: Antigenicity and speciﬁcity analysis of the ﬁve epitopes using EIA.
Number Antigen
(peptides-BSA)
Antibody to the
proteins (titer) OD value (450nm) Antigen (proteins)
Antibody to
peptides-BSA
(titer)
EIA A450 value
(1) gB2466–473/BSA gB2
(1:10 000) 0.977 ±0.039 gB2 gB2466–473/BSA
(1:5000) 1.099 ±0.037
(2) gC2216–223/BSA gC2
(1:10 000) 0.899 ±0.031 gC2 gC2216–223/BSA
(1:5000) 1.102 ±0.040
(3) gE2483–491/BSA gE2
(1:10 000) 1.102 ±0.040 gE2 gE2483–491/BSA
(1:5000) 0.893 ±0.029
(4) gG2572–579/BSA gG2
(1:10 000) 0.882 ±0.011 gG2 gG2572–579/BSA
(1:5000) 0.986 ±0.031
(5) gI2286–295/BSA gI2
(1:10 000) 0.792 ±0.029 gI2 gI2286–295/BSA
(1:5000) 0.876 ±0.031
(6) BSA All the proteins#
(1:10 000) <0.2000 All the proteins BSA∗∗ (1:5000) < 0.2000
#: BSA did not react with all the antisera to the ﬁve proteins.
∗∗: The ﬁve proteins did not react with all the antisera to BSA.
3.3. Virus Neutralization Activity of the Antisera. The virus-
neutralizationactivityoftheantiseraagainsttheﬁveepitopes
was tested using the 50% plaque reduction assay. The
results (Table 4) show that the antisera to the ﬁve epitopes
could block HSV-2 infection. The neutralization titers of
the antisera against gB2466–473 and gE2483–491were 1:256,
the neutralization titers of the antisera against gC2216–223,
gG2572–579,a n dg I 2 286–295 were 1:128, they were essentially
the same neutralization titer. On the other hand, the control
sera from the PBS-vaccinated mice and the antisera to BSA
did not show neutralization activities.
3.4. Animal Protection Experiments. The immunized mice
were intravaginally challenged with lethal dosages (5 ×
106 pfu, 500 LD50 for each mouse) of HSV-2 Sav strain. The
vaginal external diseases were examined daily for inﬂamma-
tion, and the mean daily lesion scores were measured on the
1st to the 14th day following the challenge. The severity ofClinical and Developmental Immunology 5
Table 3: Antigenicity and speciﬁcity detection of the ﬁve peptides using Western Blot analysis.
Number Antigen
(peptides-BSA)
Antibody to the
proteins (titer) Western blotting Antigen (proteins)
Antibody to
peptides-BSA
(titer)
Western blotting
(1) gB2466–473/BSA gB2
(1:10 000) ++∗ gB2 gB2466–473/BSA
(1:5000) ++
(2) gC2216–223/BSA gC2
(1:10 000) ++ gC2 gC2216–223/BSA
(1:5000) ++
(3) gE2483–491/BSA gE2
(1:10 000) +++ gE2 gE2483–491/BSA
(1:5000) +++
(4) gG2572–579/BSA gG2
(1:10 000) ++ gG2 gG2572–579/BSA
(1:5000) ++
(5) gI2286–295/BSA gI2
(1:10 000) ++ gI2 gI2286–295/BSA
(1:5000) ++
(6) BSA All the proteins#
(1:10 000) — All the proteins BSA∗∗
(1:5000) —
∗: +++, strong reaction; ++, good reaction; +, moderate reaction; —, no reaction.
#: BSA did not react with all the antisera to the ﬁve proteins.
∗∗: The ﬁve proteins did not react with the antisera to BSA.
M 12345
120
85
60
40
22
(
k
D
)
Figure 1: Western blotting results of the ﬁve peptides-BSA
to the antibodies against the parent proteins, respectively.
(1) gB2466–473/BSA, (2) gC2216–223/BSA, (3) gE2483–491/BSA, (4)
gG2572–579/BSA, (5) gI2286–295/BSA.
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Figure 2: Western blotting results of the ﬁve parent proteins to the
antibodies against the peptides-BSA, respectively. (1) gB2, (2) gC2,
(3) gE2, (4) gG2, (5) gI2.
theprimarydiseasewasassessed(1–5scores)usingthelesion
scoring system [17]. The mice in all groups immunized with
the ﬁve epitopes, respectively, were protected from death to
a certain extent at a lethal dose, whereas the mice in the
control group developed severe diseases and died, on the
3rd day after the challenge. The vaccinated mice showed
some extended protection level, and the lesion scores of
the infected mice varied among the ﬁve groups from the
4th day after the challenge (Figure 3). On the 4th day after
the challenge, the mice immunized with gB2466–473/BSA or
gE2483–491/BSA showed high protection level, with lesion
scores of less than 1, whereas the mice immunized with
gC2216–223/BSA, gG2572–579/BSA, or gI2286–295/BSA showed
relatively low protection level, with lesion scores of greater
than1.Theseresultsindicatedthattheinﬂammationseverity
of the immunized mice with the epitopes signiﬁcantly
decreased.
The survival rates of the infected mice were calculated
daily. The survival rates of all the epitope-immunized groups
ranged from 50% to 80% (Figure 4), whereas all the PBS-
vaccinated mice developed severe diseases and died between
the 3rd and 5th day after the challenge. On the 8th day after
the challenge, the survival rate of the gB2466–473-immunized
mice was highest (80%), and the survival rate of the
gE2483–491/BSA-immunized mice was 70%. Protective eﬀect
of the ﬁve epitope peptides was signiﬁcantly better than the
control group (student’s t-test, P<0.05), gB2466–473 was the
best, followed by gE2483–491, and there were not signiﬁcantly
diﬀerence in the protective eﬀect among the other three
epitope peptides (student’s t-test, P>0.05). From highest
to lowest, the protection rates of the ﬁve epitopes were
gB2466–473/BSA > gE2483–491/BSA > gC2216–223/BSA >
gG2572–579/BSA > gI2286–295/BSA. The results show that each
of the ﬁve epitopes had a partial protection eﬀect, but they
could not completely protect the mice from infection alone.6 Clinical and Developmental Immunology
Table 4: Neutralization activity of the antisera to the ﬁve epitopes.
Number Antibody to epitopes Virus (HSV-2) 50% neutralization antibody titer
(1) gB2466–473/BSA
5 × 106 pfu, 500LD50
1:256
(2) gC2216–223/BSA 1:128
(3) gE2483–491/BSA 1:256
(4) gG2572–579/BSA 1:128
(5) gI2286–295/BSA 1:128
(6) BSA 0
Lesion score of animals after challenge (n = 10)
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Figure 3: Lesion score of the immunized animals after HSV-2
challenge.
4. Discussion
Predicting the antigenic, surface-located regions (B-cell
epitopes) from the primary structure of the parent glyco-
protein was necessary to select the epitope peptides that
can stimulate mice into generating antibodies and enable
these antibodies to react with the corresponding parent
glycoproteins and neutralize the viral infectivity [18]. Some
methods have recently been developed to predict sequential
B-cell epitopes in glycoproteins (linear and conformational)
[18]. In the current study, the epitopes in glycoproteins
gB2, gC2, gE2, gG2, and gI2 of HSV-2 were predicted
because these glycoproteins play important roles in humoral
immunity. Some epitopes, such as gG2472–479, were selected
because of their high β-turn probability, hydrophilicity, and
predicted ﬂexibility [19, 20]. On the other hand, some B cell
e p i t o p e s ,s u c ha sg E 2 483–491, were selected because of their
high hydrophilicity value. Most predicted epitopes using
software algorithms had good antigenicity. For example,
gB2466–473 had high antigenicity values in the prediction
algorithms and strong reaction in the EIA tests. Only few of
the predicted epitopes had weak antigenicity. For example,
gB2468–475,g B 2 300–306,a n dg C 2 326–335 had high antigenicity
values in the prediction algorithms but had low values in the
EIA tests, indicating that predicting epitopes using software
algorithmsisusefulforselectingimmunodominantepitopes.
Survival rate of immunized animals (n = 10)
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Figure 4: Survival rates of the immunized mice after the HSV-2
challenge.
Meanwhile, other software algorithms, such as the
surface plot predictive algorithm, have also been used for
selecting the linear amino acid sequence regions (B-cell epit-
opes) of proteins [21]. The method, which included the
Chou-Fasman secondary structure, glycosylation site, and
β-turn algorithms, was similar to the prediction algorithm
in the current study. In our opinion, any prediction method
is limited for selecting the epitopes in viral proteins that may
elicit neutralizing antibodies, and none of the prediction
algorithms is signiﬁcantly better than the other methods.
Therefore, B-cell antigenic epitopes from HSV-2 glycopro-
teins were screened in the current study using three software
algorithms, namely, the Biosun, DNAstar, and Antheprot
algorithms, combined with the multiparameter algorithm.
The common results of the software algorithms were used
as candidate epitopes of B-cell epitopes. Several examples in
literature implicated that a buried region of an antigen could
be immunogenic. For example, two sites in the vpI coat pro-
tein of poliovirus induced a signiﬁcant neutralization respo-
nse in rats and rabbits, although these regions had been
showntobedeeplyburiedintheinteriorusingX-raycrystal-
lographic studies [22]. In the current study, the screened
B-cell epitopes were linear antigenic regions presented on
the surface of the molecule and were not conformational or
discontinued epitopes.Clinical and Developmental Immunology 7
The epitope (473–730aa) of gB2 had been reported to
have high antigenicity [22], which is consistent with the
results of the current study, in which the 466–473aa of gB2
is the immunodominant epitope of gB2. The epitope (210–
230aa) of gC2 was reported to be the immunodominant
epitope [23], which is consistent with the prediction in the
current study. However, the epitope (216–223aa) of gC2 was
selected in the current study because it had higher antigenic-
ity than the epitope (126–132aa) of gC2, as shown in the
EIA results. Three epitopes, namely, 350–364aa, 286–295aa,
and 526–539aa of gG2, have also been reported [24], but the
selectedepitope(472–479aa)ofgG2inthecurrentstudyhad
astrongerantigenicity.Inthecurrentstudy,theﬁvepredicted
epitopes,namely,466–473aaofgB2,216–223aaofgC2,483–
491aa of gE2, 472–479aa of gG2, and 286–295aa of gI2,
which have not been reported before were conﬁrmed using
EIA, Western Blot, and animal protection experiments.
The ﬁve predicted epitopes could induce mice into pro-
ducingspeciﬁcantibodies,andalltheantiserahadvirusneu-
tralization activities. Some previous studies have demon-
strated that neutralizing antibodies are important for the
protection against HSV-2 infection and the titer of ≥ 1:10
is considered to be indicative of protective immunity [25].
The mean neutralization titer of the antisera from the mice
immunized with gB2466–473 or gE2483–491 was 1:256, and the
mean neutralization titer of the antisera from the mice im-
munizedwithgC2216–223,gG2 572–579,orgI2 286–29gwas1:128.
These antibody titers were high enough to neutralize virus
infection. Moreover, each of the ﬁve epitope peptides could
partially protect the mice from HSV-2 infection. However,
none of the ﬁve epitope peptides could completely protect
the mice from HSV-2 infection; thus, they should be used
together as a mixed immunogens to elicit stronger and more
complete immunity protection.
5. Conclusions
Five predicted immunodominant epitope peptides, namely,
gB2466–473,g C 2 216–223,g E 2 483–491,g G 2 572–579,a n dg I 2 286–295
from glycoproteins B, C, E, G, and I of HSV-2, respectively,
were conﬁrmed via experiments. The ﬁve epitope peptides
showed excellent antigenicity and could stimulate mice into
producing speciﬁc antibodies that could neutralize HSV-2
infection in vitro. The ﬁve epitope peptides can also partially
protect mice from HSV-2 infection. Thus, these epitope
peptides may be used for HSV-2 infection diagnosis and
vaccine design.
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